APA (7th ed.) Citation

Curtis K. Johnston, Rena J. Eudy-Byrne, Ahmed Elmokadem, Valerie Nock, Jan Marquard, Nima Soleymanlou, . . . Karl-Heinz Liesenfeld. (2021). A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes. MDPI AG.

Chicago Style (17th ed.) Citation

Curtis K. Johnston, Rena J. Eudy-Byrne, Ahmed Elmokadem, Valerie Nock, Jan Marquard, Nima Soleymanlou, Matthew M. Riggs, and Karl-Heinz Liesenfeld. A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes. MDPI AG, 2021.

MLA (9th ed.) Citation

Curtis K. Johnston, et al. A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes. MDPI AG, 2021.